Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+0,47%
1 067,36
+4,96
+0,47%
—1 062,401 064,141 071,991 061,02——
SIXC
Communications
SIXC
Communications
SIXC
-0,54%
603,48
-3,26
-0,54%
—606,74606,74609,84602,33——
SIXE
Energy
SIXE
Energy
SIXE
+0,54%
1 244,93
+6,72
+0,54%
—1 238,211 236,601 247,741 232,10——
SIXI
Industrials
SIXI
Industrials
SIXI
+0,68%
1 730,38
+11,77
+0,68%
—1 718,611 723,231 741,481 717,47——
SIXM
Financials
SIXM
Financials
SIXM
+0,33%
639,47
+2,10
+0,33%
—637,37638,27642,30638,27——
SIXR
Staples
SIXR
Staples
SIXR
+0,16%
854,95
+1,36
+0,16%
—853,59854,05858,19851,34——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+0,11%
218,56
+0,23
+0,11%
—218,33218,33219,73217,15——
SIXT
Technology
SIXT
Technology
SIXT
+1,02%
3 631,59
+36,78
+1,02%
—3 594,813 620,103 657,473 615,34——
SIXU
Utilities
SIXU
Utilities
SIXU
+0,80%
915,77
+7,23
+0,80%
—908,54909,50917,35907,07——
SIXV
Health care
SIXV
Health care
SIXV
+1,19%
1 512,81
+17,81
+1,19%
—1 495,001 499,611 517,101 499,61——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,41%
2 408,21
+9,90
+0,41%
—2 398,312 406,822 421,802 404,22——
SNW:ETR
Sanofi SA
€76,90
-0,83%
(-0,64) 1D
22 Mei, 17:35:44 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for SNW...
Open
€77,62
High
€77,99
Low
€76,86
Mkt. cap
93,10 mjd
Avg. vol.
15,50 k
Volume
7,82 k
P/E ratio
12,44
52-wk high
€93,98
52-wk low
€71,81
EPS
€6,18
Shares outstanding
1,25 mjd
No. of employees
75 k
News stories
From sources across the web
Profile
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company trades as "SAN" on Euronext Paris and "SNY" on Nasdaq in the United States, and is a component of the Euro Stoxx 50 stock market index. In 2023, the company was ranked 89th in the Forbes Global 2000. Sanofi engages in the research and development, manufacturing, and marketing of pharmacological products, principally in the prescription market, but the firm also develops over-the-counter medications. The corporation covers seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines. It is one of the world's largest producer of vaccines through its subsidiary Sanofi Pasteur. Wikipedia
About Sanofi SA
CEOPaul Hudson
Employees74,8 k
Founded1973
HeadquartersParys, Île-de-France, Frankryk
SectorPharmaceutical industry
Websitesanofi.com
Last report
23 Apr. 2026
Fiscal period
Q1 2026
EPS / Est. (EUR)
€1,88 / €1,80
+4,50%beat
Revenue / Est. (EUR)
11,24 mjd / 10,23 mjd
+9,96%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
Jun. 2025
Sep. 2025
Des. 2025
Mrt. 2026
Revenue
10,74 mjd
13,17 mjd
12,20 mjd
11,24 mjd
Cost of goods sold
2,99 mjd
3,41 mjd
3,63 mjd
3,06 mjd
Cost of revenue
2,99 mjd
3,41 mjd
3,63 mjd
3,06 mjd
Research and development expenses
1,91 mjd
1,83 mjd
2,29 mjd
1,75 mjd
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,32 mjd
2,29 mjd
2,82 mjd
2,33 mjd
Operating expense
6,03 mjd
5,97 mjd
6,84 mjd
5,94 mjd
Total operating expenses
9,02 mjd
9,39 mjd
10,46 mjd
9,00 mjd
Operating income
1,71 mjd
3,78 mjd
1,74 mjd
2,25 mjd
Other non operating income
-24,00 m
-
122,00 m
-40,00 m
EBT including unusual items
1,47 mjd
3,51 mjd
-1,16 mjd
2,01 mjd
EBT excluding unusual items
1,74 mjd
3,67 mjd
1,70 mjd
2,14 mjd
Income tax expense
230,00 m
680,00 m
-348,00 m
420,00 m
Effective tax rate
15,68%
19,38%
30,13%
20,85%
Other operating expenses
1,42 mjd
1,39 mjd
1,19 mjd
1,33 mjd
Net income
3,94 mjd
2,80 mjd
-801,00 m
1,61 mjd
Net profit margin
36,70%
21,28%
-6,56%
14,35%
Earnings per share
-
-
1,53
1,88
Interest and investment income
72,00 m
114,00 m
79,00 m
60,00 m
Interest expense
-62,00 m
-227,00 m
-
-138,00 m
Net interest expenses
10,00 m
-113,00 m
79,00 m
-78,00 m
Depreciation and amortization charges
-
-
-
-
EBITDA
2,48 mjd
4,20 mjd
3,49 mjd
2,78 mjd
Gain or loss from assets sale
-266,00 m
266,00 m
-79,00 m
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer